Abstracts sources. The NHS perspective was taken and included direct costs only. In the decision analytical model, patients either receive MAL-PDT or cryotherapy first line with second line therapy depending on lesion response. A one-year time horizon was used to capture all relevant resource use and to assess the clinical response. An excellent cosmetic outcome was defined as 100% complete lesion response, but also no scarring, atrophy or induration, and no or slight occurrence of redness or change in pigmentation compared to adjacent skin. Key efficacy data from the clinical trial were subjected to a stochastic sensitivity analysis using a Beta prior distribution and 1000 simulations. RESULTS: From the deterministic model, the MAL-PDT strategy dominated cryotherapy. Seventy-three percent of patients had an excellent cosmetic outcome with MAL-PDT at a cost of £832.93 per patient compared to 42% of cryotherapy patients (£843.08 per patient). In the stochastic analysis using 1000 simulations, 95% of the ICERs were in the range -£161 to £191. MAL-PDT was the dominant in strategy in 66.3% of the simulations. CONCLUSIONS: MAL-PDT is at least as cost-effective as cryotherapy in the treatment of thin or non-hyperkeratotic actinic keratoses (AK) on the face or scalp and has superior cosmetic outcomes. To compare the annual costs of treatment incurred by a health plan for patients diagnosed with actinic keratosis (AK) and treated with fluorouracil or cryosurgery. METHODS: Pharmacy and medical claims from 2.7 million members of a managed care organization in California, Oklahoma, Oregon, Texas, and Washington, were examined. Adult patients newly treated for AK with either 5% fluorouracil cream or cryosurgery, between January 1 and December 31, 2001, were identified. Patients treated with cryosurgery were further stratified by number of lesions (i.e., 1, 2-14, >15). Disease-related health care costs (pharmacy and medical) for a 2-year follow-up period were evaluated. RESULTS: Of the 9279 identified patients, 498 (5.4%) were treated with fluorouracil and dermatologists prescribed this medication (48.4%) more often than other specialties. Among the 8781 patients treated with cryosurgery, 3004 (34.2%), 5130 (58.4%), and 647 (7.4%) were identified with 1, 2-14, and >15 lesions, respectively. Total disease-related health care costs during the follow-up period for the fluorouracil cohort averaged $509, compared to $296, $523, and $898 for the 1, 2-14, and >15 lesion cohorts, respectively. CONCLUSION: AK is a common pre-malignant lesion that can develop into squamous cell carcinoma. Numerous options are available for the treatment of AK, all of which have been shown to be equally efficacious. In this study, use of 5% fluorouracil cream for the treatment of multiple AK lesions was cost saving compared to cryosurgery. Similarly, because fluorouracil is known to treat sub-clinical lesions, additional savings may be realized for periods longer than two years. The economic burden of psoriasis varies by disease severity. Moderate to severe psoriasis requires use of systemic treatment agents and is likely to be associated with higher medical costs. OBJECTIVE: To estimate health care utilization rates and perpatient costs for the treatment of moderate to severe psoriasis. METHODS: A database of health insurance claims from 58 US commercial health plans was used to obtain patient-level data. Patients, aged 18-64, included in the analysis had a diagnosis of psoriasis, and received >1 treatment cycle of at least one of the following systemic agents: psoralen plus ultraviolet A (PUVA), methotrexate (Mtx), cyclosporine, acitretin, etretinate, ultraviolet B (UVB), and systemic corticosteroids (Cs). Patients with <6 months of observation period and those with rheumatoid arthritis and other autoimmune diseases were excluded from the analysis. RESULTS: A total of 1780 patients met all eligibility criteria noted above (Group 1). Another 282 patients were newly diagnosed patients with no prior history of claims for psoriasis (New Starts; Group 2). The most frequently used systemic therapies by patients in Group 1, over a period of 1 year, were Cs (42%), UVB (37%), PUVA (26%), and Mtx (22%). Of patients in Group 2, 56%, 37%, 31%, and 18% received UVB, Cs, PUVA, and Mtx. In an analysis of annual per-patient costs for drugs, outpatient services, and inpatient services, results were comparable for Groups 1 and 2. In Group 1, mean (median) annual per-patient costs were $917 ($473), $199 ($85), and $6 ($0), respectively and the corresponding costs for Group 2 were $744 ($412), $179 ($63), and $0 ($0), respectively. 90th percentile annual per-patient costs among all patients and New Starts were $2932 and $2125, respectively. CONCLUSIONS: Estimates of annual per-patient costs of treating moderate to severe psoriasis exceed those reported previously, and reflect a considerable direct medical burden. Patients with dermatophytosis aged 18 years and above were included in the study. Health care expenditures included costs related to prescription medications, outpatient, emergency room and inpatient visits. Predisposing factors included age, gender, race, education, and marital status. Enabling factors included insurance type, employment status, family size and income. Need factors included comorbid conditions, perceived mental and health status. Analysis of covariance was used to compare the levels of different factors affecting health care expenditures adjusting for age. Sampling weights provided by MEPS were used to provide representative estimates. RESULTS: A total of 156 patients with dermatophytosis were identified (ICD-9-CM code = 110.x). These represented 1.8 million patients nationally. The average age of patients was 51 years. The majority of the respondents were female (52%); caucasian (87%) had private insurance (80%) and was married (62%). Health care expenditures for females was significantly higher than for males ($831 vs. $450) (p = 0.03). Patients in families with less than three members spent $232 more than those in families with three or more members (p = 0.04). Patients with some college education or higher had higher health care expenditures ($718) compared with those who had attended high school ($581) or elementary
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